State Food & Drug Administration informed on Jul 16th that special supervision and examination on onboard oxygen generating system(OBOGS) in use in medical institutions of 18 provinces (Districts and cities) including Beijing, would be carried on. This measure aimed at further regulating and improving the security level of onboard oxygen generating system in the following links: registration, production, management and application, etc.

Concerning the legality and security of onboard oxygen generating system used in the medical institutions, due to the industrial oxygen event in Binzhou Children's hospital, many queries had once be incurred. Subsequently, Professor Ou Aimin and other ten professors and students from the Law College of Xiangtan University sent a letter together to the Legal Affairs Office of State Council. They requested hospitals to inspect the legality of self-produced oxygen via the onboard oxygen generating machine. Many oxygen companies also wanted to seek “answers” through litigation.

Aiming at relative questionings, State Food & Drug Administration Center for Drug Evaluation organized a seminar to discuss the relevant issues of 93% oxygen clinical security. Experts in medical device administration and clinical specialists participating in the seminar considered that clinically used oxygen generally used oxygen with relative lower concentration (<50%). Only the usage and concentration of oxygen varied in anesthesia and intensive care unit (ICU). Therefore, 93% oxygen could completely satisfy the clinical demand, which was also safety.